BNA’s Health Care Daily Report™ sets the standard for reliable, high-intensity coverage of breaking health care news, covering all major legal, policy, industry, and consumer developments in a...
By Nathaniel Weixel
Jan. 25 — Sen. Edward Markey (D-Mass.) has placed a hold on the nomination of Robert Califf to lead the Food and Drug Administration, his office said Jan. 25.
Markey in a statement said he objects to the agency's approval of the opioid OxyContin for use in children. The FDA last year approved the use for OxyContin for children as young as 11 without convening an advisory committee. The move was questioned by a group of senators, including Markey (182 HCDR, 9/21/15).
Markey called for “immediate reforms” to the agency's approval process for opioid painkillers.
“The FDA needs to commit to shift the way it approaches and evaluates addiction before I can support Dr. Califf's nomination,” Markey said in a statement. No full Senate vote has been scheduled on the nomination.
Markey isn't the only senator to place a hold on Califf. Sen. Lisa Murkowski (R-Alaska) said she will put a hold on Califf until the FDA answers questions over its labeling of genetically modified salmon. Sen. Bernie Sanders (I-Vt.) may also consider placing a hold on Califf because of his ties to the drug industry (08 HCDR, 1/13/16).
On Jan. 12, a Senate committee approved the nomination of Califf to lead the FDA. Approximately a year ago, Califf was named FDA deputy commissioner for medical products and tobacco. Before that, he was vice chancellor of clinical and translational research at Duke University.
Markey wrote a letter to Department of Health and Human Services Secretary Sylvia Mathews Burwell Dec. 21, outlining his intent to place a hold on the nomination. Markey said he had met with Califf in November and raised concerns about the agency's repeated approval of applications for powerful opioid painkillers.
“Unfortunately, Dr. Califf did not give me confidence that under his stewardship the FDA would confront the highly problematic manner in which the agency is approaching these issues,” Markey wrote in the letter.
Markey said he would only support the nomination if the FDA rescinds its pediatric approval of OxyContin and empanels an advisory committee on the question; agrees to empanel an advisory committee on any future opioid approval questions; and ensures that issues of addiction, abuse and dependence are criteria considered by the FDA when it makes opioid approval decisions.
To contact the reporter on this story: Nathaniel Weixel in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Janey Cohen at email@example.com
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)